Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Squamous Non-Small Cell Lung Cancer

Drug Information

Target Indication

Squamous Non-Small Cell Lung Cancer

Clinical Trial

Last updated: 1/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Related Pipeline

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Colorectal Cancer

Diabetes Mellitus Type 2

Muscular Atrophy, Spinal

Amyotrophic Lateral Sclerosis